PON1 polymorphisms are predictors of ability to attain HDL-C goals in statin-treated patients
| Autor: | Maria Elvira Wagner Ferreira, Renan Canibal Pires, Jéssica Aguiar de Souza, Luciana O. Lima, Luiz Carlos Van der Sand, Cézar Roberto Van der Sand, Angelica Menin, Marilu Fiegenbaum, Mara H. Hutz, Silvana Almeida, Lisiane Smiderle |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Simvastatin Statin Genotype medicine.drug_class Atorvastatin Clinical Biochemistry Gastroenterology Polymorphism (computer science) Internal medicine medicine Humans Alleles Aged Aged 80 and over biology Aryldialkylphosphatase Cholesterol HDL Paraoxonase General Medicine Cholesterol LDL Middle Aged medicine.disease PON1 Endocrinology Cardiovascular Diseases biology.protein Population study lipids (amino acids peptides and proteins) Female Dyslipidemia Brazil medicine.drug |
| Zdroj: | Clinical biochemistry. 48(16-17) |
| ISSN: | 1873-2933 |
| Popis: | Objectives PON1 plays an important role in inhibiting LDL-C oxidation, which reduces atherosclerosis and cardiovascular disease. Elevated PON1 activity or levels may contribute to increased HDL-C levels, but controversy exists over the hypothesis that genetic variation in the PON1 gene locus modulates HDL-C levels and responses to statin treatment. Therefore, the objective of this study was to investigate the association between two polymorphisms in the PON1 gene and statin responses in a south Brazilian population. Design and methods The study population included 433 dyslipidemic patients who were prescribed statins. Total cholesterol, triglyceride, HDL-C and LDL-C levels were measured in these patients both before and after approximately 6 months of treatment with simvastatin/atorvastatin. Genotypes were assessed by real-time PCR for two PON1 polymorphisms, Q192R (rs662) and L55M (rs854560). Results Baseline lipid levels were not associated with Q192R or L55M polymorphisms. For the Q192R (rs662) polymorphism, we observed that HDL-C goals were attained less often in patients with RR homozygosity than in Q allele carriers (χ2 P = 0.009, adjusted residual analysis P = 0.003). For the L55M (rs854560) polymorphism, LL homozygotes were underrepresented among subjects that achieved the HDL-C goal (χ2 P = 0.026, adjusted residual analysis P = 0.008). Analysis by univariate logistic regression confirmed that QQ/QR and MM/ML carriers had an increased chance of attaining HDL-C goals (OR = 2.41, CI95% = 1.32–4.40, P = 0.004 and OR = 1.68, CI95% = 1.15–2.45, P = 0.008). In a multivariate logistic analysis used to assess predictors of attaining an HDL-C goal > 1.55 mmol/L, we observed that gender (OR = 1.71, CI95% = 1.04–2.83, P = 0.036), baseline HDL-C levels (OR = 1.13, CI95% = 1.10–1.16, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect